{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:28:41Z","timestamp":1786739321389,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Human epidermal growth factor receptor 2 (HER-2) is a checkpoint, controlling cell proliferation and differentiation. Trastuzumab, a humanized monoclonal antibody directed against HER-2, is nowadays standard treatment for breast cancer patients whose tumors express HER-2. It is generally well tolerated, with a small number of patients developing mild adverse reactions. Dermatomyositis is a rare adverse event of trastuzumab therapy not well described in the literature. We herein present a case of a patient treated for hormone-sensitive invasive ductal carcinoma, who presented with symptoms of proximal muscle weakness, arthralgias, skin rash, and generalized fatigue. The symptoms started after the sixth cycle of trastuzumab and progressively deteriorated. The patient's medical and family history was unremarkable. Disease progression as a possible cause of dermatomyositis had been ruled out, and laboratory evaluation revealed moderate elevation of serum muscle proteins and acute-phase reactants. Trastuzumab treatment was discontinued, and 3 months later, the patient was free of symptoms without any further intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_209_19","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T04:56:48Z","timestamp":1594097808000},"page":"1112-1114","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["A case of trastuzumab-induced dermatomyositis"],"prefix":"10.4103","volume":"17","author":[{"given":"Ioannis Panagiotis","family":"Trontzas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos Konstantinos","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias Alexandros","family":"Kotteas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-46-20241021","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"R2-46-20241021","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"ESO-ESMO 2 international consensus guidelines for advanced breast cancer (ABC2)","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breast"},{"key":"R3-46-20241021","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5152\/eurjrheum.2017.17036","article-title":"An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breast cancer","volume":"4","author":"Reynolds","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"R4-46-20241021","first-page":"57","article-title":"Dermatomyositis induced by trastuzumab (Herceptin\u00ae)","volume":"32","author":"Guillemotonia","year":"2013","journal-title":"J Pharm Clin"},{"key":"R5-46-20241021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the treatment of breast cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"R7-46-20241021","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel","volume":"21","author":"Leyland-Jones","year":"2003","journal-title":"J Clin Oncol"},{"key":"R8-46-20241021","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0b013e3283317fa5","article-title":"Paraneoplastic myopathy","volume":"21","author":"Dank\u00f3","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R9-46-20241021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","article-title":"Drug-related myopathies of which the clinician should be aware","volume":"12","author":"Valiyil","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"R10-46-20241021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: Updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_209_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:57Z","timestamp":1786735677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_209_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_209_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}